Cardiovascular Sciences (CE) (USOTC:CVSC)
Historical Stock Chart
From Jun 2019 to Jun 2024
The board of directors of Cardiovascular Sciences, Inc. (Pink
Sheets:CVSC) (the "Company") is eager to announce that it is entering
into the next phase of development with its partnership with MedTech
Enterprises. Cardiovascular Sciences, Inc. is a client company of the
award-winning University of Central Florida's Technology Incubator
program. MedTech Enterprises is the company’s
division readying to spring forth with a retail internet program to
market a premium antioxidant, anti-aging nutritional supplement.
Over the past six weeks, the company has arranged for the production of
a premium antioxidant supplement containing nutrients scientifically
proven to reduce cholesterol levels which may reduce the risk of heart
disease when taken with a diet low in saturated fats and cholesterol.
The production of the product is nearing completion and a label for the
Company’s Cell Renewal Formula has cleared the
regulatory compliance hurdle. The product is scheduled for release later
this month.
“We are very enthused and anxious to launch
our supplement which has been formulated to include the latest
developments in the area of antioxidant supplementation,”
exclaims the company’s President/CEO, Dr.
Larry Hooper. “In addition to our direct
marketing, we have also met recently with a number of individuals
interested in carrying our proprietary core antioxidant to a variety of
markets.”
In addition to the Company’s core product
entry into this field, a number of vendor agreements have been reached
to distribute a number of additional health-benefiting products. The
company envisions growing a line of various select and complementary
products, all with a focused goal of benefiting health, enabling
prevention and insuring longevity.
Jev Conover, a member of the board of directors and the CEO of a
prominent hospital in the Midwest, added, “We
see this endeavor to develop a line of products with prominent health
benefits as a natural extension of the Company’s
continuing efforts to develop its antiadhesion technology whose benefits
are also to insure improved health and prevent illness and disability.”
About Cardiovascular Sciences, Inc.
Cardiovascular Sciences, Inc. is an advanced medical device company
which is developing a novel technology platform to address the problem
of post-surgical and post-traumatic adhesions. Adhesions and the
complications of adhesions are a significant problem worldwide for a
wide range of specialists, including general surgeons, cardiothoracic
surgeons, orthopedic, plastic, and ophthalmologic and otolaryngology
specialists to name just some of them. In addition, the veterinary field
has a tremendous need for a product that can prevent similar problems in
a wide variety of animals. The Company's unique materials and processes
promise a more cost-effective and decidedly more efficient and capable
means to deal with a problem that has been so devastating to so many.
Current sponsored research at the University of Central Florida (UCF)
and previously at other institutions indicate that The Company is on the
right path and progressing well.
In addition to the anti-adhesion technology, The Company owns technology
in a variety of other areas, including thrombo-resistant coatings,
enhanced intra-arterial balloon pumping catheters, cell-engineered
vascular tissues, and a method for improved recovery of the heart
following cardioplegia. This yields a diversified portfolio with
projects in various stages of development. www.cvsciences.org
Forward-looking statements in this release are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to certain risks, and
uncertainties and actual results could differ from those discussed. This
material is information only and is not an offer or solicitation to buy
or sell the securities.